Alcoholic Hepatitis Market Size to Reach US$ 3.1 Billion by 2034, Impelled by Advancements in Early Detection

Alcoholic Hepatitis Market Outlook 2024-2034:

The alcoholic hepatitis market size reached a value of US$ 1.9 Billion in 2023. Looking forward, the market is expected to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.37% during 2024-2034. The market is driven by the increased emphasis on early detection and diagnosis, advances in biomarkers, and diagnostic technologies, such as novel blood and urine tests. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Alcoholic Hepatitis Market 

Advances in early detection and diagnostic technologies for alcoholic hepatitis (AH) have become crucial in improving patient outcomes, given the high morbidity and mortality associated with the disease. Additionally, liver biopsies are increasingly being replaced with non-invasive imaging methods, including magnetic resonance elastography (MRE) and transient elastography (TE). These methods quantify hepatic stiffness, which is correlated with AH's hallmarks of inflammation and fibrosis. TE has gained popularity due to its accessibility, speed, and accuracy in staging liver disease, whereas MRE offers more comprehensive imaging and greater sensitivity in detecting early-stage fibrosis. Moreover, emerging diagnostic technologies allow for earlier, more precise detection, which benefits the alcoholic hepatitis market by increasing access to timely care and creative treatment techniques. Apart from this, the early diagnosis of alcoholic hepatitis may be improved by developments in biomarker identification. Some biomarkers have been studied as possible indicators of liver inflammation and injury, such as soluble CD163, a sign of macrophage activity, and cytokeratin-18, a marker of hepatocyte death. By evaluating these markers noninvasively through blood tests, AH can be identified early before severe symptoms manifest. To further aid in a more accurate diagnosis and even more individualized treatment plans, metabolomic and proteomic profiling methods are being developed to identify particular patterns of alcohol-induced liver damage.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of innovative therapeutics and pharmacological treatments is crucial to growing the ischemic stroke market. The advancement of novel therapies for alcoholic hepatitis has become an area of intense research due to the severe nature of the disease and the limited efficacy of traditional treatments. Standard treatments like corticosteroids have been demonstrated to have varying effects on survival rates, especially in individuals with severe AH. Moreover, researchers are exploring new therapy approaches for people with alcoholic hepatitis, such as targeted pharmaceuticals, immune-modulating therapies, and regenerative medicine. Anti-inflammatory and immune-modulating medications are one of the most promising approaches to treating AH. Alcoholic hepatitis is characterized by severe inflammation and an exaggerated immune response that leads to hepatocellular damage. Current research focuses on targeting important inflammatory pathways, particularly TNF-α and IL-1. For example, TNF-α inhibitors, including infliximab and etanercept, have been studied for their ability to reduce inflammation and enhance liver function in AH patients. Furthermore, early trials have shown promise for regenerative medicine approaches, including the use of stem cell therapy. Mesenchymal stem cells (MSCs) have anti-inflammatory, immunomodulatory, and regenerative capabilities, which may aid in the repair of damaged liver tissue in AH patients. Apart from this, anti-fibrotic agents, which aim to reduce liver scarring and promote liver regeneration, are being studied. Drugs such as simtuzumab, which targets lysyl oxidase-like 2 (an enzyme involved in collagen cross-linking), have been tested in liver diseases with fibrosis, including AH, with the hope of slowing disease progression.

Emerging Therapies in Alcoholic Hepatitis Market

DUR-928: DURECT Corporation 

DUR-928 is an endogenous sulfated oxysterol and epigenetic regulator. It represents a novel class of medicines with a distinct mechanism of action. DUR-928 epigenetically modifies the expression of many master gene clusters implicated in numerous critical cells signaling pathways, thereby stabilizing mitochondria, lowering lipotoxicity, regulating inflammatory or stress responses, and promoting cell survival.

INT-787: Intercept Pharmaceuticals

INT-787 is Intercept's next-generation farnesoid X receptor (FXR) agonist. The drug is a synthetic bile acid that is being studied as a therapy for severe alcohol-associated hepatitis due to its anti-inflammatory and anti-fibrotic effects in animal models. INT-787 has also been demonstrated to have hepatoprotective effects, such as reduced liver lipids, galectin-3, and Col1a1.

Detailed list of emerging therapies for Alcoholic Hepatitis is provided in the final report.

Key Players in Alcoholic Hepatitis Market:

The key players in the Alcoholic Hepatitis market who are in different phases of developing different therapies are DURECT Corporation, Intercept Pharmaceuticals, and Others.

Regional Analysis:

The major markets for alcoholic hepatitis include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for alcoholic hepatitis while also representing the biggest market for its treatment. This can be attributed to the rising incidence of alcohol use disorder and heavy alcohol consumption, which have led to a growing burden of AH cases.

Moreover, advancements in non-invasive diagnostic technologies, such as transient elastography and biomarker-based tests, also drive market growth by enabling earlier and more accurate diagnosis, which is essential for timely intervention.

Besides this, the inflating utilization of anticoagulant medicines, such as heparin and warfarin, to help in preventing blood clot formation and diminishing the risk of recurrent stroke, is bolstering the market growth in the U.S. Additionally, the increasing focus on personalized medicine and targeted therapies has propelled interest in novel pharmacological treatments that address the underlying mechanisms of AH. Investment in research and development from pharmaceutical companies and the rising awareness of liver diseases due to public health campaigns further contribute to the expansion of the AH treatment market in the U.S., creating a favorable environment for new product launches.

Recent Developments in Alcoholic Hepatitis Market:

• In December 2022, DURECT Corporation announced that DUR-928 had been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis, also known as alcohol-associated hepatitis.
• In November 2022, Intercept Pharmaceuticals announced that it would focus the development of its next-generation FXR agonist, INT-787, on severe alcohol-associated hepatitis (sAH). Initial data from Intercept's ongoing Phase 1 trial of INT-787 in healthy subjects were presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., and supported INT-787's favorable safety and tolerability profile in healthy male and female adults. The organization had also launched the FRESH (FXR Effect on Severe Alcohol-Associated Hepatitis) research, a Phase 2a trial, to assess the safety, tolerability, effectiveness, and pharmacokinetics of INT-787 in sAH patients.

Key information covered in the report

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the alcoholic hepatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the alcoholic hepatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current alcoholic hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800